MedWatch

Are drug companies keeping tabs on each other?

Pharmaceutical companies are keeping a watchful eye on their rivals and the access to marketing authorizations of other companies reveal highly useful information. But drug companies are not lining up to admit to this practice, records of the companies’ access to documents reveal.

Useful information can be hidden in the marketing authorizations of rival pharmaceutical companies, but it is difficult to gauge exactly how big a role access to documents play in the industry, as drug companies are somewhat reluctant to reveal just how often they ask for access to rivals’ marketing authorization.

Over the last five years the Danish Health and Medicines Authority has received 39 requests for access to marketing authorizations from drug companies, according to official numbers from the agency. But several experts estimate the actual numbers to be much higher.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Genmab-partner trækker sig fra samarbejde

Abbvie ønsker ikke længere at udvikle en fælles kræftkandidat med Genmab, men biotekselskabet skal stadig betale royalites af et eventuelt fremtidigt salg ved kommercialisering.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier